UNSPSC 51111849: Fosfestrol

This classification denotes a hormonal antineoplastic agent with the molecular formula C18H22O8P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A0E0NMA80F, chemically known as 4,4-stilbenediol, .alpha., .alpha.-diethyl-, diphosphate, disodium salt but generally known as fosfestrol, which bears US NIH Compound Identifier 3032325. European Medicines Agency schedules Fosfestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07795MIG.

UNSPSC 51111849 Fosfestrol is a Commodity code covering generic pharmaceutical products and over-the-counter medications sourced through state and local cooperative purchasing vehicles. State and local government facilities — including state departments, counties, municipalities, and other participating jurisdictions in multistate cooperatives — procure these products primarily through cooperative purchasing agreements that establish fixed pricing, supply chain agreements with authorized wholesalers, and standardized product specifications tied to National Drug Codes (NDC). The work entails manufacturers submitting comprehensive pharmaceutical product catalogs with pricing, product identification codes (NDC, SKU, UPC), strength, dosage form, packaging configuration, and manufacturing location, then fulfilling orders through designated wholesaler networks on a two-year contract term with optional extensions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The RFP requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencara, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain contractual relationships with at least two of the three, demonstrate cGMP and Drug Supply Chain Security Act (DSCSA) compliance, and accept pricing structures including flat price, net price formats (NF30, NF60, NF90), or WAC-minus arrangements. Evaluation prioritizes price competitiveness (75 percent), with smaller weights on fixed pricing, administrative fee compliance, EDI capability, and willingness to accept a 3 percent administrative fee. Products must be available in the marketplace by May 15, 2026, with resulting contracts effective July 1, 2026, and vendors must carry commercial general liability coverage of $5,000,000 per occurrence and professional liability of $2,000,000.